+
Suven Pharmaceuticals Renamed as Cohance Lifesciences
ECONOMY & POLICY

Suven Pharmaceuticals Renamed as Cohance Lifesciences

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences.

This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics.

The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide.

"The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world" said Cohance Executive Chairman, Vivek Sharma.

The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation.

The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences. This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics. The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide. The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world said Cohance Executive Chairman, Vivek Sharma. The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Next Story
Real Estate

Omaxe to Develop 450-Acre Township in Indore’s Super Corridor

Omaxe has announced a major expansion in Madhya Pradesh with the acquisition of 450 acres along Indore’s Super Corridor for a modern integrated township. The company will invest Rs 12 billion in the multi-phase project, which is expected to generate Rs 25 billion in revenue over three years.  The development will include residential clusters, commercial and retail zones, schools, healthcare facilities, parks, and green mobility infrastructure. The township aims to support the region’s urban growth and rising infrastructure demand, especially with metro connectivity and major road..

Next Story
Infrastructure Energy

India’s First CBG Plant with Steel Pipeline Integration Launched

CEID Consultants and Engineering has successfully commissioned India’s first Compressed Biogas (CBG) plant integrated via a steel pipeline into a City Gas Distribution (CGD) network. Located in Batala, Gurdaspur (Punjab), the MEPL Bio-energy facility now directly supplies CBG into Gujarat Gas’ grid, eliminating the need for cylinder-based cascade transport and significantly lowering logistics costs. This breakthrough comes after CEID’s earlier deployment of MDPE pipeline offtake at the same plant. The steel pipeline marks a new industry benchmark, enabling continuous, real-time and ..

Next Story
Real Estate

Mittal Builders Plans Landmark Township to Transform Naigaon

Mittal Builders has unveiled a bold urban vision to transform Naigaon into a landmark micro-market in western Mumbai, with plans to unlock 6.5 million sq. ft. of development potential across a 70-acre land parcel. The long-term multi-phase plan has an estimated gross development value (GDV) of over Rs 80 billion. As part of this initiative, Mittal Builders has signed a joint development agreement with The House of Abhinandan Lodha (HoABL) to co-develop a 3 million sq. ft. integrated township, comprising over 4,600 apartments and high-street retail. With a planned investment of Rs 20 billi..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?